Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (181 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2009-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 14.7% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 100% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patient hasbladderhas knownoabincontinence
  Phrases that lowered it: tolerabilityrelevantto assessassess thepatients who
• Minimum age: 20 (lowers risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Design: single group (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 246 (raises risk) · Sponsor's track record
• Sponsor's past trials: 360 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 1 (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder. NCT00611026 · started 2008 · scored riskier than 9% of active trials completed
• Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children. NCT02614482 · started 2015 · scored riskier than 21% of active trials completed
• Evaluation Of The Ability Of Fesoterodine To Increase Urethral Pressure In Stress Urinary Incontinence Patients NCT01042236 · started 2009 · scored riskier than 70% of active trials completed
• Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years NCT00857896 · started 2009 · scored riskier than 51% of active trials completed
• Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children NCT02327936 · started 2014 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.